A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 31 Oct 2019 Planned End Date changed from 14 Feb 2021 to 6 Jun 2021.
- 31 Oct 2019 Planned primary completion date changed from 14 Feb 2021 to 6 Jun 2021.
- 24 Sep 2019 Planned End Date changed from 6 Jun 2021 to 14 Feb 2021.